Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05050097 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Study acronym: MonumenTAL-2
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 67 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from Apr 7, 2027 to Dec 31, 2027 Show 1 more changeShow less
    • Completion pushed from Apr 7, 2027 to Dec 31, 2027
  2. Re-verified, no change to tracked fieldsv66
  3. Completion moved earlier from Oct 13, 2027 to Apr 7, 2027v65
  4. Re-verified, no change to tracked fieldsv64
  5. Completion pushed from Apr 7, 2027 to Oct 13, 2027v63
Show 45 earlier versionsHide 45 earlier versions
  1. 15 versions Re-verified since Feb 27, 2025, no change to tracked fieldsv48-v62
  2. Completion date: Apr 1, 2027 to Apr 7, 2027v47
  3. Re-verified, no change to tracked fieldsv46
  4. Primary completion date: Jul 2, 2025 to Mar 31, 2025 Completion date: Sep 23, 2025 to Apr 1, 2027v45 Show 1 more changeShow less
    • Completion date: Sep 23, 2025 to Apr 1, 2027
  5. Re-verified, no change to tracked fieldsv44
  6. Completion date: Jul 17, 2025 to Sep 23, 2025v43
  7. Enrollment target: 167 to 166v42
  8. Re-verified, no change to tracked fieldsv41
  9. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 182 to confirmed 167 · Completion date: Sep 29, 2025 to Jul 17, 2025 · Site details revised at 31 of 31 sitesv40 Show 3 more changesShow less
    • Enrollment target: estimated 182 to confirmed 167
    • Completion date: Sep 29, 2025 to Jul 17, 2025
    • Site details revised at 31 of 31 sites
  10. Completion date: Oct 1, 2025 to Sep 29, 2025v39
  11. Study sites revised (31)v38 See this version in full on ClinicalTrials.gov ↗
  12. Completion date: Aug 5, 2025 to Oct 1, 2025v37
  13. Re-verified, no change to tracked fieldsv36
  14. Study sites revised (31)v35 See this version in full on ClinicalTrials.gov ↗
  15. Primary completion date: Dec 31, 2024 to Jul 2, 2025 Study sites revised (31)v34 Show 1 more changeShow less
    • Study sites revised (31)

    See this version in full on ClinicalTrials.gov ↗

  16. 2 versions Re-verified since Jan 2, 2024, no change to tracked fieldsv32-v33
  17. Study sites revised (31)v31 See this version in full on ClinicalTrials.gov ↗
  18. Re-verified, no change to tracked fieldsv30
  19. Primary completion date: Sep 30, 2024 to Dec 31, 2024v29
  20. 4 versions Re-verified since Jun 28, 2023, no change to tracked fieldsv25-v28
  21. Primary completion date: Aug 15, 2023 to Sep 30, 2024v24
  22. Enrollment target: 192 to 182 Study sites: 30 to 31v23 Show 1 more changeShow less
    • Study sites: 30 to 31
  23. Study sites: 35 to 30v22
  24. Enrollment target: 182 to 192v21
  25. Enrollment target: 176 to 182 Site details revised at 2 of 35 sitesv20 Show 1 more changeShow less
    • Site details revised at 2 of 35 sites
  26. Site details revised at 1 of 35 sitesv19
  27. Study Status, Contacts/Locationsv18
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Trial Details
NCT Number NCT05050097
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 166 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov